Secondary endpoints addressing skin lesions
SECONDARY
Significantly more dupilumab-treated patients achieved an IGA PN-S score of 0 or 1 (‘clear’ or ‘almost clear’, ≤5 nodules) in each trial at week 24: PRIME, 48.0% versus 18.4% (95% CI for the difference, 13.4–43.2; Supplementary (as-observed and hybrid method) analyses results for primary and key secondary endpoints in both trials were consistent with the primary analysis, confirming the robustness of results (Extended Data Table 